Ad
related to: what is epon and gpon treatment for cancer cells
Search results
Results from the WOW.Com Content Network
APON/BPON, EPON and GPON have been widely deployed. In November 2014, EPON had approximately 40 million deployed ports and ranks first in deployments. [47] As of 2015, GPON had a smaller market share, but is anticipated to reach $10.5 billion US dollars by 2020. [48] For TDM-PON, a passive optical splitter is used in the optical distribution ...
[5] [6] [7] These anti-mitotic effects lead to cell death, slowing cancer growth. [ 5 ] [ 6 ] [ 7 ] A TTField-treatment device manufactured by the Israeli company Novocure is approved in the United States and Europe for the treatment of newly diagnosed and recurrent glioblastoma , malignant pleural mesothelioma (MPM), and is undergoing clinical ...
Following the publication of 40 Gbps NG-PON2 in July 2015, standardization activities turned to higher speed PON. [4] In November 2016, the Full Service Access Network (FSAN) Group released the Standards Roadmap 2.0 which indicated the development of "future optical access systems" with peak transmission rates above 10 Gbps.
This compares to the IEEE 802.3av standard for 10G-EPON based on Ethernet, which has standardised upstream rates of both 1 Gbit/s and 10 Gbit/s. [8] The 10 gigabit PON wavelengths (1577 nm down / 1270 nm up) differ from GPON and EPON (1490 nm down /1310 nm up), allowing it to coexist on the same fibre with either of the gigabit PONs. [9]
Like all EPON networks, 10G-EPON transmits data in variable-length packets up to 1518 bytes, as specified in the IEEE 802.3 standard. These variable-length packets are better suited to IP traffic than the fixed-length, 53-byte cells used by other Passive Optical Networks, such as GPON. This can significantly reduce 10G-EPON's overhead in ...
The GPON OMCI recommendation G.984.4 draws on G.983.2, which defines the BPON management model. However, G.984.4 removed all references to ATM. G.988 is a stand-alone OMCI recommendation and supersedes G.984.4 except for GPON specifics that are not defined in G.988. Future work on the PON management model is expected to appear only in the GPON ...
Neutron capture therapy is a binary system that consists of two separate components to achieve its therapeutic effect. Each component in itself is non-tumoricidal, but when combined they can be highly lethal to cancer cells. 1) Boron compound (b) is selectively absorbed by cancer cell(s). 2) Neutron beam (n) is aimed at cancer site.
T-cell transfer therapy: a treatment that takes T-cells from the tumor and selects or changes them in the lab to better attack cancer cells, then reintroduces them into the patient. Monoclonal antibodies: designed to bind to specific targets on cancer cells, marking cancer cells so that they will be better seen and destroyed by the immune system.
Ad
related to: what is epon and gpon treatment for cancer cells